New research has shown that the burden of meningitis in babies unchanged in 25 years

New research by Professor Paul Heath funded by Meningitis Research Foundation has shown that the burden of meningitis in babies under three months of age has changed little in the past 25 years.

Babies under three months of age are 70 times more at risk of developing than adults and about one in 10 of these babies will not survive.

This latest study, funded by Meningitis Research Foundation and carried out at St George's, evaluated the burden of bacterial meningitis in babies and compared it with figures from previous studies in the 1990s and 1980s.

Between July 2010 and July 2011, the research team identified 364 cases of bacterial meningitis in infants aged under three months in the UK and Ireland

In nearly 300 of these babies, scientists were able to isolate and identify bacteria, and found that in half of cases, Group B Streptococcus (GBS) was the cause. This is relatively unchanged since 1997, despite a national GBS prevention policy introduced in 2003 which guides the use of antibiotics in labour for women whose babies are at higher risk of GBS in the first week of life.

Professor Paul Heath said: "GBS prevention using antibiotics, can only have an impact on early onset disease which are babies aged under seven days, meaning there are still late-onset cases contributing significantly to the burden of meningitis and septicaemia in neonates.

"Clearly a better strategy for preventing GBS infection is now required."

The good news is that, there are vaccines against GBS in development, including one in clinical trials in pregnant women.

Christopher Head, Chief Executive of Meningitis Research Foundation said: "July is GBS awareness month and this latest research has shown that meningitis is still a very real threat to our children despite them being protected later in life from a number of strains.

"We are now committed to funding a follow on project to this study, looking at the longer term outcomes of bacterial in and how this can be used in cost-effectiveness calculations of future GBS vaccines."

The cases in the study were identified either through the British Paediatric Surveillance Unit, Public Health England, Health Protection Scotland and the Irish Meningococcal, and Meningitis Reference Laboratory or through charities including Meningitis Research Foundation's national helpline.

The results have recently been published in the journal Clinical Infectious Diseases.

Related Stories

More accurate diagnostic test may reduce deaths

date Jun 26, 2012

A more accurate, faster diagnostic test for Group B Streptococcal infection in babies has been reported in the Journal of Medical Microbiology. The new test could allow better treatment and management of the disease and re ...

A new strategy for developing meningitis vaccines

date May 24, 2012

Bacterial meningitis is an infection of the meninges, the protective membrane that covers the spinal cord and brain. Children, elderly patients and immunocompromised patients are at a higher risk for the development of severe ...

Recommended for you

'Ebola will return', veteran scientist warns

date 1 hour ago

Congolese expert Jean-Jacques Muyembe may be little known to the public, but he has been one of the world's top Ebola investigators since the first epidemic erupted in central Africa in 1976.

Score IDs patients with upper extremity DVT at low risk

date 16 hours ago

(HealthDay)—For patients with upper-extremity deep vein thrombosis (DVT), six easily available factors can be used to create a score that identifies those at low risk of adverse events during the first ...

Combined drug treatment combats kidney disease

date May 29, 2015

A recent discovery by drug researchers whereby coupling specific cell membrane receptors has altered kidney cell function has triggered a re-think of how to treat chronic kidney disease (CKD) more effectively.

Active substance targeting dreaded hospital germs

date May 29, 2015

In the German Center for Infection Research (DZIF), scientists have conducted clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: a highly effective protein from bacteriophages ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.